Financial Performance - The company recorded a revenue growth of 11.6%, reaching HKD 801.0 million for the year ended December 31, 2024[4] - Profit for the year increased by 21.8% to HKD 70.9 million, with a net profit margin rising to 8.9% from 8.1% in 2023[4] - Operating profit for the year was HKD 79.7 million, up from HKD 65.8 million in 2023[5] - The group's revenue for 2024 reached HKD 800,963,000, an increase from HKD 717,973,000 in 2023, representing an increase of approximately 11.5%[22] - The total profit for the reporting segment rose to HKD 100,401,000 in 2024, compared to HKD 90,548,000 in 2023, marking an increase of 10.2%[32] - The company reported a basic and diluted earnings per share of HKD 69,167,000 for 2024, compared to HKD 57,275,000 in 2023, reflecting a significant increase in profitability[43] Revenue Segmentation - Revenue from the imaging disposable products segment increased by 37.7% to HKD 393.3 million, attributed to strengthened collaboration with major clients and growth in the global medical imaging diagnostic services market[4] - Revenue from OEM products was HKD 631,477,000 in 2024, up from HKD 505,520,000 in 2023, reflecting a growth of about 24.9%[22] - Revenue from external customers in the United States reached HKD 292,736,000 in 2024, up from HKD 259,719,000 in 2023, reflecting a growth of 12.7%[33] - Revenue from external customers in Spain surged to HKD 256,594,000 in 2024, compared to HKD 168,738,000 in 2023, indicating a significant increase of 52.0%[33] - Revenue from the imaging disposable products segment reached HKD 393.3 million in 2024, a 37.7% increase from HKD 285.6 million in 2023, accounting for 49.1% of total revenue[48] - The respiratory products segment experienced a revenue decline of 10.7% to HKD 245.5 million in 2024, down from HKD 274.9 million in 2023, primarily due to reduced demand[50] - Revenue from orthopedic support and rehabilitation products decreased by 14.4% to HKD 50.2 million in 2024, down from HKD 58.7 million in 2023, reflecting pressures from macroeconomic uncertainties[51] - Other products revenue increased by 13.2% to HKD 111.9 million in 2024, up from HKD 98.8 million in 2023, representing 14.0% of total revenue[52] Dividends - The board proposed a final dividend of HKD 0.017 per share, totaling HKD 0.033 per share for 2024, compared to HKD 0.0275 per share in 2023[4] - The company has approved a final dividend of HKD 1.5 per share for 2023, totaling approximately HKD 9,800,000, and a mid-term dividend of HKD 1.6 per share for 2024, totaling approximately HKD 10,453,000[10] - The board has declared a final dividend of 1.7 HKD cents per share for the year, up from 1.5 HKD cents in 2023, bringing the total dividend for 2024 to 3.3 HKD cents per share[87] Assets and Liabilities - Total assets increased to HKD 919.7 million from HKD 786.6 million in 2023[8] - Non-current assets rose significantly to HKD 332.0 million from HKD 214.0 million in 2023, driven by investments in property, plant, and equipment[8] - The company’s total equity increased to HKD 583.4 million from HKD 543.1 million in 2023[9] - Contract assets increased to HKD 31,613,000 in 2024 from HKD 14,820,000 in 2023, indicating a significant rise of approximately 113%[24] - The group reported a decrease in trade receivables to HKD 169,332,000 in 2024 from HKD 172,394,000 in 2023, a decline of approximately 1.8%[24] - Trade receivables amounted to HKD 169.3 million, with the quality of receivables being satisfactory and credit risk management continuing to be a focus[69] - The company’s inventory as of December 31, 2024, was HKD 162.7 million, down from HKD 173.8 million in 2023, reflecting strict inventory policies[68] Operational Efficiency - The company focused on quality and compliance management, obtaining certification under the EU Medical Device Regulation for its quality management system and respiratory product series[4] - The company implemented efficiency-enhancing measures, including optimizing procurement channels and upgrading its ERP system[4] - The company is focused on digitalization, automation, and operational optimization to improve workflow and efficiency across its business management systems[47] - The new production facility in Jiangmen, Guangdong Province, is on track to commence trial operations by the end of 2025, aimed at enhancing operational efficiency[47] - Capital expenditure for the year was HKD 142.4 million, significantly up from HKD 21.3 million in 2023, primarily for the construction of new production facilities[65] - The company plans to continue building new production facilities, expected to commence trial operations by the end of 2025[56] Research and Development - Research and development expenditure was HKD 30.6 million, representing 3.8% of total revenue, down from 5.0% in 2023[62] - The company plans to continue investing in R&D and seek strategic partnerships to accelerate business development, particularly in the context of its collaboration with Inovytec Medical Solutions Limited[53] Financial Standards and Compliance - The group has adopted revised Hong Kong Financial Reporting Standards effective from January 1, 2024, which includes changes in the classification of liabilities[14] - The group has not made any retrospective adjustments due to the adoption of the revised standards, and there was no significant impact on previously recognized amounts[15] - The group is currently evaluating the expected impact of new standards and interpretations that will become effective in the future, including those effective from January 1, 2025, and beyond[18][19] Miscellaneous - The company has not made any significant acquisitions or disposals of subsidiaries or associates during the year[80] - As of December 31, 2024, the company has no contingent liabilities reported[85] - The company has pledged assets including properties and equipment valued at 132.7 million HKD and right-of-use assets at 30.4 million HKD to secure loans for new production facilities[82] - The company has not engaged in any purchase, sale, or redemption of its listed securities during the year[96] - There are no significant events reported after the reporting period up to the date of this announcement[81] - The company has not established a foreign currency hedging policy despite exposure to currency risks, particularly with costs denominated in RMB and sales in USD and JPY[83] - The annual general meeting is scheduled for May 21, 2025, with a record date for the final dividend on June 2, 2025[86]

Vincent Medical 永 勝 醫 療 控 股 有 限 公 司 力： 200 - 100 - 0 ● Al Reliability 可靠 B o 中期報号 | --- | --- | --- | |-------|-------|------------------------------| | | | | | | | | | | 目 | 錄 | | | | | | 2 | | 公司資料 | | 3 | | 財務摘要 | | 4 | | 管理層討論及分析 | | | 10 | 其他資料 | | | 23 | 獨立審閱報告 | | | 24 | 簡明綜合損益表 | | | 25 | 簡明綜合損益及其他全面收益表 | | | 26 | 簡明綜合財務狀況表 | | | 27 | 簡明綜合權益變動表 | | | 28 | 簡明綜合現金流量表 | | | 29 | 簡明綜合財務報表附註 | 公司資料 | --- | --- | --- | |-------------------------------------------------------------------|------------------ ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Vincent Medical Holdings Limited 永勝醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1612） 截至2024年6月30日止六個月之 中期業績公告 | --- | --- | |-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of HKD 500 million, representing a growth of 25% year-over-year[2]. - Revenue for the year ended December 31, 2023, increased by 14.1% to HKD 717.973 million compared to HKD 629.242 million in 2022[15]. - The company reported a profit attributable to owners of HKD 57.275 million, a turnaround from a loss of HKD 17.398 million in 2022[15][24]. - Basic earnings per share improved to HKD 8.87 from a loss of HKD 2.66 in the previous year[15]. - The total dividend for 2023 was HKD 2.75 per share, an increase from HKD 2.50 in 2022, with a payout ratio of 31.4%[24]. - The group recorded a profit attributable to owners of HKD 57.3 million, a significant recovery from a loss of HKD 17.4 million in 2022[52]. - The company reported a net profit margin of 15%, up from 12% in the previous year, indicating improved operational efficiency[3]. Revenue Segmentation - Revenue from disposable imaging products grew by 20.0% to HKD 285.6 million, up from HKD 238.0 million in 2022[27]. - The imaging disposable products segment reported a revenue increase of 20.0% to HKD 285.6 million, accounting for 39.8% of total revenue[35]. - The respiratory products segment generated revenue of HKD 274.9 million, a 9.6% increase, representing 38.3% of total revenue, primarily due to a 10.2% increase in sales of inspiredTM respiratory devices and consumables[32]. - The healthcare and wellness products segment saw a significant revenue increase of 195.6% to HKD 26.9 million, reflecting the expansion of the product portfolio[37]. Strategic Initiatives - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 20%[3]. - New product launches included the O2FLO respiratory humidification device, which is expected to contribute an additional HKD 50 million in revenue[3]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[3]. - A strategic acquisition of a local medical device company was completed, enhancing the company's product portfolio and expected to generate HKD 30 million in synergies[3]. - The company plans to upgrade its operational systems and enhance marketing capabilities in 2024, alongside increased investment in technology and product innovation[29]. - The strategic focus includes expanding into health care and wellness devices, enhancing product offerings and business sustainability[25]. Research and Development - Research and development expenses increased by 18%, totaling HKD 80 million, focusing on innovative medical technologies[3]. - Research and development expenses for the year amounted to HKD 36.1 million, representing 5.0% of total revenue, a decrease from 5.8% in 2022[49]. - The company is constructing a new R&D and production facility in Jiangmen, Guangdong, to enhance production capacity and operational efficiency[28]. - The company plans to focus on product development, customer relationship management, and clinical education to enhance product competitiveness and order visibility in the respiratory products segment[40]. Governance and Compliance - The company has implemented a new corporate governance policy aimed at improving transparency and accountability[3]. - The board of directors has approved a dividend policy, with a proposed dividend of HKD 0.05 per share, reflecting a payout ratio of 25%[3]. - The company has established a risk management committee to enhance operational oversight and mitigate potential risks[72]. - The company has confirmed the independence of all independent non-executive directors through annual independence confirmation letters[141]. - The company reported no significant violations of applicable laws and regulations during the year[121]. Market Risks and Challenges - The company faces significant financial risks, including foreign currency risk, credit risk, liquidity risk, and interest rate risk[109]. - The ongoing geopolitical tensions and political instability may adversely affect the company's operations and increase costs[98]. - Labor shortages and rising labor costs are impacting the company's ability to maintain production levels[101]. - The company is exposed to supply chain disruptions, which could delay product deliveries and harm its reputation[102]. - The potential for new COVID-19 variants remains a concern, which could disrupt economic activities and the company's operations[95]. - The company is subject to strict regulatory compliance, and changes in laws or regulations could limit its ability to operate effectively[106]. Employee and Shareholder Relations - The total number of full-time employees increased to 1,264 from 1,226 in 2022, with total employee costs, including directors' remuneration, amounting to HKD 194.3 million, which is 27.1% of total revenue[61]. - The company focuses on creating a harmonious and safe working environment for employees, offering competitive compensation and professional training[115]. - The company emphasizes the importance of effective communication with shareholders and aims to provide stable and sustainable returns[117]. Share Options and Incentives - The company has granted a total of 2,000,000 stock options to Mr. Cai, subject to vesting conditions[157]. - The total number of unexercised stock options as of December 31, 2023, is 1,986,668 shares after accounting for cancellations[171]. - The share options plan allows for the issuance of options to executives, directors, employees, and other eligible participants as a reward for their contributions[167]. - The total number of shares that may be issued as rewards under the share incentive plan is capped at 32,820,516 shares, representing approximately 5% of the company's issued share capital as of the adoption date[182]. Continuous Connected Transactions - The company has entered into continuous connected transactions, including a medical trolley procurement agreement and a plastic and metal service agreement with VRDG[196]. - The medical trolley procurement agreement is effective from June 30, 2021, to December 31, 2023, while the plastic and metal service agreement is effective from January 1, 2022, to December 31, 2023[197]. - The annual cap for the medical trolley procurement agreement is set at HKD 22,000,000 for the year ending December 31, 2023[200]. - The annual cap for the plastic and metal service agreement is set at HKD 11,500,000 for the year ending December 31, 2023[200].

智通财经APP讯，永胜医疗(01612)发布截至2023年12月31日止年度的全年业绩，该集团期内取得收入7.18亿港元，同比增加14.1%;股东应占溢利5727.5万港元，上年同期股东应占亏损1739.8万港元，同比扭亏为盈;每股基本盈利8.87港仙;拟派发末期股息每股1.5港仙。 公告称，呼吸产品分部仍是集团增长战略的组成部分，并于2023年重回增长轨道，收入按年增长9.6%至2.75亿港元(2022年：2.51亿港元)，占集团收入的38.3%。该增长主要由于集团的inspiredTM呼吸类器械及耗材的采用率持续上升，销售额增长10.2%所致。 ...

Financial Performance - The company achieved a robust organic revenue growth of 14.1% to HKD 718.0 million for the year ended December 31, 2023, with imaging disposable products growing by 20.0% and respiratory products by 9.6%[4]. - The company turned a profit in 2023, recording a net profit attributable to shareholders of HKD 57.3 million, compared to a net loss of HKD 17.4 million in 2022[4]. - The group’s total revenue for 2023 reached HKD 717,973,000, an increase from HKD 629,242,000 in 2022, representing a growth of approximately 14.1%[24]. - The company reported a gross profit of HKD 240.4 million for 2023, compared to HKD 165.4 million in 2022, reflecting a gross margin improvement[5]. - Operating profit for the year was HKD 65.8 million, a significant turnaround from an operating loss of HKD 11.0 million in the previous year[5]. - The overall segment profit for 2023 was HKD 90,548,000, compared to HKD 13,796,000 in 2022, indicating a significant improvement[34]. - The company reported a consolidated profit before tax of HKD 66,915,000, a turnaround from a loss of HKD 15,516,000 in the previous year[34]. - The company's profit for 2023 was HKD 57,275,000, a significant recovery from a loss of HKD 17,398,000 in 2022[43]. Revenue Breakdown - Revenue from respiratory products amounted to HKD 274,853,000 in 2023, up from HKD 250,802,000 in 2022, reflecting an increase of about 9.6%[24]. - Revenue from imaging disposable products was HKD 285,570,000 in 2023, compared to HKD 238,021,000 in 2022, marking an increase of approximately 19.9%[24]. - The group’s revenue from orthopedic support and rehabilitation devices was HKD 58,704,000 in 2023, down from HKD 69,064,000 in 2022, reflecting a decrease of about 15.0%[24]. - The group’s revenue from the United States market was HKD 259,719,000 in 2023, a decrease from HKD 354,565,000 in 2022, representing a decline of approximately 26.7%[24]. - The group’s revenue from Spain increased significantly to HKD 168,738,000 in 2023 from HKD 8,175,000 in 2022, indicating a substantial growth of approximately 1955.5%[24]. - The OEM segment generated revenue of HKD 505,520,000, up from HKD 435,602,000, representing a growth of 16.0%[34]. - The OBM segment reported revenue of HKD 212,453,000, an increase of 9.7% from HKD 193,640,000[34]. Dividends and Shareholder Returns - The board declared a final dividend of HKD 0.015 per share for the year, resulting in a total dividend of HKD 0.0275 per share for 2023, up from HKD 0.025 per share in 2022, with a payout ratio of 31.4%[4]. - The total dividend for 2023 is HKD 2.75 per share, with a payout ratio of 31.4%, compared to HKD 2.5 per share in 2022[88]. - The company plans to distribute a final dividend of HKD 1.5 per share, pending shareholder approval at the upcoming annual general meeting[42]. Assets and Liabilities - Total assets increased to HKD 786.6 million in 2023 from HKD 726.7 million in 2022, with total equity rising to HKD 543.1 million from HKD 498.6 million[8]. - The company’s cash and cash equivalents increased to HKD 175.8 million in 2023 from HKD 159.3 million in 2022, indicating improved liquidity[8]. - The company’s non-current assets totaled HKD 213.9 million in 2023, up from HKD 177.4 million in 2022, reflecting ongoing investments in fixed assets[8]. - The company’s total borrowings decreased to HKD 21.0 million from HKD 38.5 million in 2022, resulting in a net capital debt ratio of 0.04, down from 0.08[76]. - The company has no contingent liabilities as of December 31, 2023[86]. - The company has no assets pledged as collateral as of December 31, 2023[83]. Operational Efficiency and Strategy - The company plans to focus on long-term development by enhancing production efficiency, expanding capacity, and automation, alongside adopting a "Made in China for China" strategy to improve profitability[4]. - The company has commenced construction of a new production facility in Jiangmen, Guangdong, to enhance operational efficiency and support new product categories[49]. - The company plans to complete a new production facility in Jiangmen, Guangdong by the end of 2025, which is expected to enhance capacity and automation, facilitating market expansion in China[59]. - The company reported a decrease in inventory provisions from HKD 34,913,000 in 2022 to HKD 4,678,000 in 2023, indicating improved inventory management[39]. Research and Development - The company continues to invest in research and development, regulatory compliance, and quality assurance to expand its product portfolio and support long-term growth strategies[4]. - Research and development expenses for the year were HKD 36.1 million, representing 5.0% of total revenue, slightly down from 5.8% in 2022[66]. Employee and Governance - As of December 31, 2023, the total number of full-time employees was 1,264, an increase from 1,226 in 2022[77]. - Employee costs, including directors' remuneration, amounted to HKD 194.3 million, representing 27.1% of the group's revenue, down from 30.6% in 2022[77]. - The board of directors includes executive directors and independent non-executive directors, ensuring a diverse governance structure[101]. Miscellaneous - The group adopted revised Hong Kong Financial Reporting Standards effective from January 1, 2023, which did not have a significant impact on the financial position or performance for the current and prior years[16]. - The group expects that the adoption of new accounting standards will not significantly affect the consolidated financial statements in the future[21]. - There were no significant acquisitions or disposals of subsidiaries or associates during the year[81]. - The board has not established a foreign currency hedging policy, but it monitors foreign currency risks closely[84]. - The annual general meeting is scheduled for May 22, 2024[87]. - The annual performance announcement and annual report for the year ending December 31, 2023, will be sent to shareholders and available on the company's website[99]. - The board expresses gratitude to stakeholders and business partners for their continuous support, acknowledging the contributions of management and all employees[100].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 Vincent Medical Holdings Limited 永 勝 醫 療 控 股 有 限 公 司 （於開曼群島註冊成立之有限公司） （股份代號：1612） 有關2022年報之補充公告 謹此提述永勝醫療控股有限公司（「本公司」）於2023年4月20日刊發截至2022年12月 31日止年度的年報（「2022年報」）。除非文義另有所指，本公告所用詞彙及用語與 2022年報所定義者具有相同涵義。 除2022年報第42頁至44頁標題章節「於2016年6月24日採納之購股權計劃」所披露者 外，董事會就2022年報第44頁的表格附註提供補充資料（修訂內容以下劃線顯示） 如下： 附註： 股份於2022年6月10日（即緊接授出購股權日期前的日期）的收市價為0.70港元。 於2022年6月13日的授出日期，購股權的估計公平值約為3,388,000港元，其按各類承授人細分如下： 承授人 於授出日期的購股權公平值 ...

Financial Performance - Revenue for the first half of 2023 reached HKD 361.2 million, a 28.7% increase from HKD 280.7 million in the same period of 2022[7] - Gross profit for the first half of 2023 was HKD 118.8 million, compared to HKD 36.8 million in the first half of 2022, reflecting a significant improvement[7] - The company reported a profit of HKD 27.1 million for the first half of 2023, a turnaround from a loss of HKD 44.3 million in the same period of 2022[7] - The basic earnings per share for the first half of 2023 was HKD 4.10, compared to a loss of HKD 6.78 per share in the first half of 2022[7] - The total revenue for the period was HKD 361.2 million, an increase of 28.7% compared to HKD 280.7 million in the first half of 2022[29] - The company recorded a profit attributable to owners of HKD 26.6 million, a significant turnaround from a loss of HKD 44.4 million in the first half of 2022[38] - The company reported a total comprehensive income of HKD 11,760,000 for the period, compared to a loss of HKD 62,929,000 in 2022[106] - The company reported a profit of HKD 26,600,000 for the six months ended June 30, 2023, compared to a loss of HKD 44,363,000 in the same period of 2022[152] - Basic earnings per share for the six months ended June 30, 2023, was HKD 0.041, compared to a loss per share of HKD 0.068 in 2022[152] Revenue Segmentation - The respiratory products segment generated revenue of HKD 155.6 million, accounting for 43.1% of total revenue, with a 27.5% increase from HKD 122.0 million in the first half of 2022[19] - Revenue from the imaging disposable products segment was HKD 125.7 million, accounting for 34.8% of total revenue, a 35.8% increase from HKD 92.6 million in the first half of 2022[22] - Revenue from other products rose by 45.1% to HKD 44.9 million, driven by increased sales of surgical patient warming devices and healthcare equipment[26] - Sales in the Chinese market surged by 112.6% to HKD 82.1 million, accounting for 22.7% of total revenue[29] - Revenue from the United States decreased to HKD 123,520,000, down 20.6% from HKD 155,630,000 in 2022, while revenue from China increased significantly to HKD 82,116,000 from HKD 38,630,000[142] Cost and Expenses - Research and development expenses for the period were HKD 18.1 million, representing 5.0% of total revenue, compared to 5.9% in the first half of 2022[36] - Employee costs, including directors' remuneration, amounted to HKD 96.7 million for the first half of 2023, representing 26.8% of the group's revenue, down from 34.5% in the same period of 2022[45] - The company incurred a net cash outflow from investing activities of HKD 10,950,000 for the six months ended June 30, 2023, compared to HKD 4,478,000 in the previous year[112] - The income tax expense for the six months ended June 30, 2023, was HKD 5,275,000, a significant increase from HKD 658,000 in the same period of 2022[144] Assets and Liabilities - Total assets as of June 30, 2023, were HKD 690,015,000, down from HKD 726,699,000 at the end of 2022[109] - Current assets decreased to HKD 525,942,000 from HKD 549,258,000 at the end of 2022[109] - The company’s total equity as of June 30, 2023, was HKD 508,197,000, compared to HKD 521,101,000 as of January 1, 2023[110] - The company’s total liabilities decreased from HKD 98,350,000 as of January 1, 2023, to HKD 98,000,000 as of June 30, 2023[110] Share Options and Capital - The company has a total of 2,646,668 unexercised share options as of June 30, 2023, with a weighted average exercise price of HKD 0.80[169] - The company granted 14,300,000 share options at an exercise price of HKD 0.80 on May 28, 2018, with 25% vesting each year from 2019 to 2022[171] - The company has a total of 32,590,332 unexercised stock options as of June 30, 2023, with 29,222,332 remaining after accounting for cancellations and expirations[77] - The company declared an interim dividend of HKD 0.0125 per share for the period, compared to no dividend in the first half of 2022[56] Corporate Governance and Compliance - The company has adopted the corporate governance code as its own governance principles, emphasizing effective internal controls and risk management[88] - The board of directors is committed to maintaining high standards of corporate governance to enhance shareholder value[88] - The independent review report for the interim financial results for the six months ended June 30, 2023, was conducted in accordance with the relevant standards[94] Future Plans and Investments - The company plans to expand product applications in new markets to sustain growth in the respiratory products segment[19] - The company plans to build new production facilities in Jiangmen City, Guangdong, with a groundbreaking ceremony held on June 30, 2023, and operations expected to commence gradually in 2025[28] - The significant investment in Inovytec, a company specializing in medical devices, was valued at USD 3.0 million (approximately HKD 23.4 million) as of June 30, 2023, representing a 13.68% equity stake[47] Employee and Management Changes - As of June 30, 2023, the total number of full-time employees in the group was 1,262, an increase from 1,226 on December 31, 2022[45] - The company appointed Dr. Liang Mingzhu as a non-executive director on July 25, 2023[186] Related Party Transactions - The company reported related party transactions, including administrative service fees of 0 thousand HKD in 2023, down from 126 thousand HKD in 2022[181] - The company sold goods to an associated company amounting to 13,987 thousand HKD in 2023, significantly up from 4,648 thousand HKD in 2022[181]

Financial Performance - The company reported a total revenue of HKD 200 million for the fiscal year 2022, representing a year-over-year increase of 15%[2] - Revenue for the year ended December 31, 2022, was HKD 629,242,000, a decrease of 19% from HKD 777,720,000 in 2021[12] - The company reported a loss attributable to shareholders of HKD 17,398,000, compared to a profit of HKD 60,695,000 in 2021[12] - The basic loss per share for 2022 was HKD 2.66, compared to earnings of HKD 9.28 per share in 2021[12] - The gross profit for 2022 was HKD 165,353,000, down 36% from HKD 259,104,000 in 2021[12] - The gross profit margin improved to 45%, up from 40% in the previous year, due to cost optimization measures[2] - The gross margin for the respiratory products segment fell from 38.3% in 2021 to 20.6% in 2022, a decline of 17.7 percentage points[39] - The gross profit decreased by 36.2% to HKD 165.4 million, leading to a gross margin drop from 33.3% to 26.3% due to inventory provisions and reduced sales volume[53] User Growth and Market Expansion - User data indicated a growth in active users by 25%, reaching a total of 1.5 million users by the end of 2022[2] - The company provided a positive outlook for 2023, projecting a revenue growth of 20% based on new product launches and market expansion strategies[2] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[2] - The company aims to expand its market influence in China by actively seeking partnerships in the post-pandemic era[30] - The company is focusing on market expansion strategies, particularly in the Asia-Pacific region, to capture emerging market opportunities[93] Research and Development - Investment in R&D increased by 30% in 2022, focusing on the development of the O2FLO respiratory humidification device[2] - R&D expenditure for the year was HKD 36.7 million, representing 5.8% of total revenue, compared to 5.0% in 2021[59] - The company has over 100 engineers and a strong R&D capability, supporting its business transformation and market expansion[18] - Ongoing research and development efforts are being prioritized, with an investment of $DD million allocated for innovative technologies[82] - The company is actively involved in innovation and technology support programs, enhancing its product pipeline and market competitiveness[94] Product Development and Launches - The company announced the launch of two new products in Q1 2023, which are anticipated to contribute an additional HKD 50 million in revenue[2] - New product development initiatives include the launch of the "inspiredTM" medical device line, aimed at enhancing market competitiveness[93] - The company aims to expand its product portfolio beyond respiratory products to tap into unique markets[29] - The company aims to expand its product portfolio by developing more types of disposable imaging products and rehabilitation medical devices[51] Financial Management and Dividends - The company’s dividend policy remains consistent, with a proposed dividend of HKD 0.05 per share, reflecting a payout ratio of 30%[2] - The company maintained a total dividend per share of HKD 2.5, down from HKD 4.5 in the previous year[12] - The company declared a special dividend of HKD 0.025 per share on September 30, 2022, totaling HKD 2.5 per share for the year ended December 31, 2022, down from HKD 0.045 per share in 2021[132] - The company has adopted a dividend policy to distribute at least 30% of the consolidated profit attributable to shareholders for each financial year, subject to the board's discretion[135] Operational Challenges - The ongoing COVID-19 pandemic and potential new variants pose significant risks to the company's business operations and financial performance[107] - Global economic uncertainties, including inflation and geopolitical risks, may adversely affect the company's financial condition and operational performance[104] - The company faces challenges related to supply chain disruptions and potential increases in component prices due to political instability and military tensions[108] - Labor costs have increased, and the company is experiencing a labor shortage, which may adversely affect its business and financial performance[111] - Supply chain disruptions could lead to delays in product delivery or cancellations, harming the company's reputation and relationships with distributors and consumers[114] Corporate Governance and Compliance - The board of directors emphasized a commitment to environmental, social, and governance (ESG) initiatives, aiming for a 50% reduction in carbon emissions by 2025[2] - The company emphasizes the importance of compliance with regulatory requirements in the medical device industry, as changes in laws and regulations could adversely affect its operations[116] - The company has complied with all relevant laws and regulations without any significant violations during the year[130] Shareholder Information - The company has a total of 653,336,332 shares issued[170] - Major shareholder Ms. Liao Peiqing held 391,189,890 shares, representing approximately 59.88% of the company's equity[169] - The top five customers accounted for 58.3% of total sales in the current year, with the largest customer contributing 39.9% of sales, compared to 29.3% in 2021[150] - The company repurchased a total of 1,746,000 shares at a total cost of HKD 1,555,820 during the year, with the aim of enhancing earnings per share[145] Risk Management - The company is exposed to various financial risks, including foreign currency risk, credit risk, liquidity risk, and interest rate risk[120] - Product quality issues could lead to significant financial liabilities and damage to the company's reputation, despite having product liability insurance[117] - Climate change poses risks to the company's operations and supply chain, potentially leading to financial and operational disruptions[119]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Vincent Medical Holdings Limited 永 勝 醫 療 控 股 有 限 公 司 （於開曼群島註冊成立之有限公司） （股份代號：1612） 截至2022年12月31日止年度之 全年業績公告 及 暫停辦理股份過戶登記手續 摘要 ² 截至2022年12月31日止年度（「2022年」或「本年度」）的收入為629.2百萬港 元，較去年（2021年：777.7百萬港元）減少19.1%。然而，本年度的下半年 仍較上半年錄得顯著改善。 ² 相較於截至2022年6月30日止六個月錄得44.4百萬港元，虧損收窄乃主要由 於2022年下半年本集團呼吸類器械的市場需求增加令存貨撥備減少及整體 產品價格調整所致。 ² 成像一次性產品分部錄得強韌增長，收入按年增長11.3%，並佔收入的 37.8%。 ...